Navigation Links
Gene therapy slows progression of fatal neurodegenerative disease in children
Date:5/13/2008

New Rochelle, NY, May 13, 2008Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children, according to a paper published online ahead of print in the May 2008 issue (Vol. 19 No. 5) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper is available free online at www.liebertpub.com/hum

Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is an autosomal recessive genetic disorder that causes degeneration of the central nervous system. It is a form of Batten disease, a group of lysosomal storage disease in which a lipofuscin-like material is not broken down and accumulates in neurons, causing cognitive impairment, visual failure, seizures, and progressive deterioration of motor function.

Ronald Crystal and colleagues from Weill Cornell Medical College (New York, NY), describe a study conducted in 10 children with LINCL who received gene therapy to replace the defective CLN2 gene via administration of human CLN2 carried in an adeno-associated virus (AAV). In the paper entitled Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis with CNS Administration of a Serotype 2 Adeno-associated virus expressing the CLN2 cDNA, the authors report that over an 18-month period, assessment using a neurologic rating scale demonstrated significant slowing of disease progression in the treated, compared to the untreated children. On the basis of these findings, the authors proposed that additional studies to assess the safety and efficacy of AAV-mediated gene therapy for LINCL be pursued.

Although the treatment was associated with some serious adverse events in some patients, these were not unequivocally attributable to the gene therapy vector.

This clinical trial is an important step toward the development of treatments for this group of underserved inherited neurodegenerative disorders, says James M. Wilson, MD, PhD, Editor-in-Chief and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, at the University of Pennsylvania School of Medicine, in Philadelphia.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
2. Cell-based therapy shows promise in patients with Parkinsons disease
3. Cancer immunotherapy shows long-term promise in lung cancer
4. Effective cancer immune therapy through order in the blood vessels
5. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
6. Biomarkers allow doctors to match therapy to patient
7. MU researcher links hormone replacement therapy to breast cancer
8. Potential new target for multiple sclerosis therapy
9. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
10. Umbilical cord blood cell therapy in an animal model of Alzheimers disease
11. Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... , December 22, 2016 SuperCom (NASDAQ: ... secure solutions for the e-Government, Public Safety, HealthCare, and Finance sectors ... SuperCom, has been selected to implement and deploy a community-based supportive ... Northern California , further expanding its presence in the ... This new ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL anunció ... acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar a ... con múltiples sitios previstos a lo largo de Europa y Norteamérica. ... MSC-1 es el ... de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ciertos ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical ... spectrum of drug and device development, and Prism Clinical Research , a ... today announced Verified Clinical Trials (VCT) has been selected by both ...
(Date:1/19/2017)... BETHESDA, Md. , Jan. 18, 2017  Northwest ... company developing DCVax® personalized immune therapies for operable and ... Marnix Bosch , Chief Technical Officer of NW Bio, ... Thursday, January 19, 2017, at the Hyatt Regency Hotel ... Dr. Bosch will chair the session entitled "New Therapeutic ...
(Date:1/19/2017)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ), ... a live webcast of its Annual Meeting of Shareholders on Tuesday, ... webcast can be accessed from the BD corporate website at ... 2017. ... BD BD is a global medical technology company that is ...
(Date:1/18/2017)... 2017 According to a new market research report "In ... Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research Institutions) - Global ... 739.9 Million by 2021 from USD 557.1 Million in 2016, growing at a ... ... MarketsandMarkets Logo ...
Breaking Biology Technology: